• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, September 21, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

British Journal of Cancer press notice

Bioengineer by Bioengineer
August 1, 2018
in Cancer
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Please download the papers below or contact the BJC press office for the full paper or with any other questions on 0203 469 8300, out of hours, 07050 264 059 or [email protected]. Scientists can be directly contacted regarding media interviews using the contact details provided.

Please reference the British Journal of Cancer in any media activity.

Paper: Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer
Corresponding author: Naomi Boekel
Telephone: +31205126292
E-mail: [email protected]

Author summary: Both radiotherapy and anthracycline-based chemotherapy are commonly used and highly effective breast cancer treatments. Unfortunately, they have also been associated with increased cardiovascular disease (CVD) risks. We studied the separate and combined effects of various treatments and established cardiovascular risk factors on the long-term risks of different CVDs in 14,645 breast cancer patients.

During 1970-2009, especially irradiation of the lymph nodes behind the sternum (IMC-irradiation) exposed the heart to high heart doses. This type of radiation is associated with ~2-fold increased rates of different CVDs compared to women receiving the lowest cardiac doses. In patients with an established cardiovascular risk factor, 20-year cumulative incidence of ischemic heart disease is 11% in patients with IMC-irradiation versus 6% in those without. Anthracyclines are associated with a four-fold increased heart failure rate, and combined with IMC-irradiation, a substantial, nine-fold increased rate was observed.

Current radiation techniques expose the heart to lower doses, and radiation-associated CVD risks are hence expected to be lower in patients treated today.

Post embargo link: https://www.nature.com/articles/s41416-018-0159-x

DOI: s41416-018-0159-x

Paper: The value of using the faecal immunochemical test in general practice on patients presenting with non-alarm symptoms of colorectal cancer
Corresponding author: Jakob Søgaard Juul, MD, PhD
Telephone: 0045 61777404
E-mail: [email protected]

Author summary: The vast majority of individuals with colorectal cancer (CRC) are diagnosed via the general practitioner (GP). One of the major challenges is that about half of these patients present with vague and non-specific symptoms that do not raise suspicion of CRC. This makes it difficult for the GP to discover the cancer early. The present study is the first to investigate the use of a safe, low-cost faecal immunochemical test (FIT) in patients presenting with non-alarm symptoms of CRC in general practice. The results suggest that the FIT may be used in this patient population to detect CRC and other serious bowel diseases in primary care and that the stage distribution of detected CRC by this method may be favourable. The findings are of importance in a realistic diagnostic work-up of patients with non-alarm symptoms of CRC and it reveals a possible diagnostic supplement in general practice.

Post embargo link: https://www.nature.com/articles/s41416-018-0178-7

DOI: s41416-018-0178-7

Paper: Detection of Circulating Tumor Cell Clusters in Human Glioblastoma
Corresponding author: Prof Nicola Aceto
Telephone: +41-61-207-0773
E-mail: [email protected]

Author summary: Human glioblastoma (GBM) is a highly aggressive malignant brain cancer. Circulating tumor cells (CTCs) are cancer cells that detach from a solid tumor lesion and enter the bloodstream, in the form of single CTCs or multicellular clusters (CTC clusters). Individual CTCs are sporadically found in GBM patients, yet, it has been unclear whether CTC clusters are generated in this disease and whether they can bypass the physical hurdle of the blood-brain barrier.

When analyzing the blood of 13 GBM patients, we observed CTC clusters at multiple sampling time-points in a patient with pleomorphism and extensive necrosis. DNA sequencing of these GBM CTC clusters highlighted alterations in 58 cancer-associated genes, many of which were also mutated in cells within the primary GBM tumor, but non-mutated in healthy cells from the same patient.

Thus, our findings represent the first evidence of the presence of CTC clusters in GBM, suggesting that clustered cancer cells are able to bypass the blood-brain barrier.

Post embargo link: https://www.nature.com/articles/s41416-018-0186-7

DOI: s41416-018-0186-7

###

The British Journal of Cancer is editorially independent of Cancer Research UK. The BJC is one of the most-cited general cancer journals, publishing significant advances in translational and clinical cancer research. It also publishes high-quality reviews and thought-provoking comment on all aspects of cancer prevention, diagnosis and treatment. The BJC is owned by Cancer Research UK and published by Springer Nature.

Media Contact

Stephanie McClellan
[email protected]
44-203-469-5314
@CR_UK

http://www.cancerresearchuk.org

Share12Tweet7Share2ShareShareShare1

Related Posts

Reticulocalbin-1: Biomarker and Therapy Target in RCC

September 20, 2025

Next-Gen Oncology: Precision Genomics Meets Immuno-Engineering

September 20, 2025

Prostate-Specific Antigen Testing: Past, Present, Future

September 20, 2025

Bisabolol: Natural Anticancer Agent with Therapeutic Promise

September 20, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    156 shares
    Share 62 Tweet 39
  • Physicists Develop Visible Time Crystal for the First Time

    68 shares
    Share 27 Tweet 17
  • Tailored Gene-Editing Technology Emerges as a Promising Treatment for Fatal Pediatric Diseases

    49 shares
    Share 20 Tweet 12
  • Scientists Achieve Ambient-Temperature Light-Induced Heterolytic Hydrogen Dissociation

    48 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

CT Scans in Kids: Cancer Risk Insights

Revealing Tendon Changes from Rotator Cuff Tears

Caffeine Exposure Shapes Neurodevelopment in Premature Infants

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.